Form 4: Cidara Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Daniel D. Burgess acquired 2,125 stock options in Cidara Therapeutics on July 18, 2024.
Summary
- Daniel D. Burgess, a director of Cidara Therapeutics, acquired 2,125 stock options on July 18, 2024.
- The exercise price of these options is $12.64.
- The options vest on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2025 annual meeting of stockholders.
- The options expire on July 17, 2034.
- Following the transaction, Burgess directly owns 2,125 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 07/18/2024 | Date of stock option transaction |
| 07/18/2025 | Earliest vesting date of the stock options |
| 07/17/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.